---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-053659"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:43:31.829402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics expands license from Factor Bioscience, gains know-how and multi-tier sublicense rights

## Summary
- Amended & Restated Exclusive License Agreement dated Nov 14, 2023 expands Eterna's rights to include necessary know-how and multi-tier sublicensing.
- CEO Matthew Angel is co-founder, President, CEO and director of Factor's parent company, creating a related-party transaction.
- Licensor's termination rights are reduced; technology transfer to Eterna is now included subject to use restrictions.
- Original agreement was from Feb 20, 2023, amended July 12, 2023; this restatement replaces it entirely.

## SEC filing metadata
- accession: 0001140361-23-053659
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/0001140361-23-053659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/ef20014811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-053659
- JSON: https://secwatch.observer/filing/0001140361-23-053659.json
- Plain text: https://secwatch.observer/filing/0001140361-23-053659.txt

## Key facts
- Material Agreements
  Ernexa Therapeutics Inc. entered into Exclusive Amended and Restated License Agreement with Factor Bioscience Limited (effective 2023-11-14).
  - Action: entry
  - Agreement: license
  - Counterparty: Factor Bioscience Limited
  - Effective: 2023-11-14
  source text: On November 14 , 2023, Eterna Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Exclusive Amended and Restated License Agreement (the “A&R Agreement”) with Factor Bioscience Limited (“Factor”) to replace in its entirety the Exclusive License Agreement dated February 20, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123053659/0001140361-23-053659-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.